Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-05-19
2000-10-10
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544358, 544380, 544382, 544398, 544403, A61K 31495, C07D24104, C07D29500
Patent
active
06130221&
ABSTRACT:
Compositions comprising a pharmaceutically effective amount of a compound that impedes disruption of intact dense microspheres (DMS) by acting on DMS either to prevent disruption, or if disrupted, act on pre-disrupted DMS in such a way that, when the composition is administered to a test animal that has received an injection of DMS, it reduces the mean volume of tissue occupied by disrupted DMS, reduces the ratio of the number of inflammatory cells per DMS, or increases the ratio of the number of macrophages containing disrupted DMS per DMS, are useful for treating cerebral amyloidosis. The compound that impedes disruption of intact DMS is represented by the following general Formula (A): ##STR1##
REFERENCES:
patent: 3028428 (1962-03-01), Van Der Stelt
patent: 3060242 (1962-10-01), Gordon et al.
patent: 4540564 (1985-09-01), Bodor
patent: 4816416 (1989-03-01), Averback
patent: 4919915 (1990-04-01), Averback
patent: 5231170 (1993-07-01), Averback
patent: 5280032 (1994-01-01), Ono et al.
patent: 5567720 (1996-10-01), Averback
H. Morren et al.: "Nouvelles substances antihistaminiques a action prolongee: les 1-4 bis (aralcoyl) piperazines" vol. 60, 1951, pp. 282-295, XP002079758 Oxford GB.
XP-002079758 Morren et. al., Bull. Soc. Chim. Belg., Nouvelles Substances Antihistaminiques a Action Prolongee: les 1-4 bis (aralcoyl) Piperazines, vol. 60 (1951), pp. 282-295.
Averback, "Parasynaptic Corpora Amylacea in the Striatum" Arch Pathol Lab Med 105:334-335 (1981).
Averback, "Unusual Particles in Motor Neuron Disease" Arch Pathol Lab Med 105:490-493 (1981).
Blessed et al., "The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects" Brit. J. Psychiat 114:797-811 (1968).
Tomlinson et al., "Observations on the Brains of Non-Demented Old people" Journal of the Neurological Sciences 7:331-356, 1968.
Tomlinson et al., "Observations on the Brain of Demented Old People" Journal of the Neurological Sciences 11:205-242 (1970).
Corsellis, "Ageing and the Dementias" Greenfield's Neuropathology pp. 796-848 (1976).
Averback, "Dense Microspheres in Normal Human Brain" Acta Neuropathologica 61:148-152 (1983).
Hara, "Microscopic Globular Bodies in the Human Brain" Journal of Neuropathology and Experimental Neurology 45:169-178 (1986).
Kono et al., Is it Useful to Manage Alzheimer's Disease as Two Clinical Subtypes: Early Onset and Late Onset Subtypes? Basic, Clinical, and Therapeutic Aspects of Alzheimer's and parkinson's .
Brandt et al., "Relation of Age at Onset and Duration of Illness to Cognitive Functioning in Alzheimer's Disease" Neuropsychiatry, Neuropsychology, and Behavioral and Behavioral Neurology, 1989, vol. 2, No. 2, pp. 93-101.
Knesevich et al., "Aphasia, Family History, and the Longitudinal Course of Senile Dementia of the Alzheimer Type" Psychiatry Research 14:255-263 (1985).
Wisniewski, Neuritic (Senile) Plaques and Filamentous Changes in Aged Rhesus Monkeys Journal of Neuropathology and Experimental Neurology pp. 566-584 (1973).
Selkoe et al., "Conservation of Brain Amyloid Proteins in Aged Mammals and Humans with Alzheimer's Deseade" Science 235:873-877, 1987.
Averback Paul
Beheshti Iraj
Ghanbari Hossein
Morse David
Nymox Corporation
Shah Mukund J.
Truong Tamthom N.
LandOfFree
Pharmaceutical agents that impede the initiation and progression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical agents that impede the initiation and progression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical agents that impede the initiation and progression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257166